Antimalarial interaction of quinine and quinidine with clarithromycin

Parasitology

Volumn 140, Issue 3, 2013, Pages 406-413

  Pandey, Swaroop Kumar ^a,b   Dwivedi, Hemlata ^a   Singh, Sarika ^a   Siddiqui, Waseem Ahmad ^b   Tripathi, Renu ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

clarithromycin; drug resistance; malaria; quinidine; quinine

Indexed keywords

CLARITHROMYCIN; QUINIDINE; QUININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; ANTIMALARIALS; CLARITHROMYCIN; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; MALE; MICE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; QUINIDINE; QUININE;

EID: 84874178755     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S003118201200176X     Document Type: Article

References (44)

1. Achan, J., Talisuna, A. O., Erhart, A., Yeka, A., Tibenderana, J. K., Baliraine, F. N., Rosenthal, P. J. and D'Alessandro, U. (2011). Quinine, an old anti-malarial drug in a modern world: Role in the treatment of malaria. Malaria Journal 10, 144
2. Awasthi, A., Dutta, G. P., Bhakuni, V. and Tripathi, R. (2004). Resistance reversal action of ketoconazole against mefloquine resistance of Plasmodium yoelii nigeriensis (MDR). Experimental Parasitology 107, 115-119
3. Barat, L. M. and Bloland, P. B. (1997). Drug resistance among malaria and other parasites. Infectious Disease Clinics of North America 11, 969-987
4. Bhattacharya, A., Mishra, L. C., Sharma, M., Awasthi, S. K. and Bhasin, V. K. (2009). Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisinin against Plasmodium falciparum In vitro. European Journal of Medicinal Chemistry 44, 3388-3393
5. Calza, P., Medana, C., Padovano, E., Giancotti, V. and Baiocchi, C. (2012). Identification of the unknown transformation products derived from clarithromycin and carbamazepine using liquid chromatography/highresolution mass spectrometry. Rapid Communications in Mass Spectrometry 26, 1687-1704
6. Champney,W. S., Tober, C. L. and Burdine, R. (1998). A comparison of the inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by nine different macrolide antibiotics. Current Microbiology 37, 412-417
7. Damkier, P. and Brosen, K. (2000). Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clinical Pharmacology & Therapeutics 68, 199-209
8. Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., Ringwald, P., Silamut, K., Imwong, M., Chotivanich, K., Lim, P., Herdman, T., An, S. S., Yeung, S., Singhasivanon, P., Day, N. P. J., Lindegardh, N., Socheat, D. and White, N. J. (2009). Reduced in-vivo susceptibility of Plasmodium falciparum to artesunate in Western Cambodia. New England Journal of Medicine 361, 455-467
9. Dorne, J. L. C. M., Walton, K. and Renwick, A. G. (2003). Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food and Chemical Toxicology 41, 201-224
10. Einarson, A., Phillips, E., Mawji, F., D'Alimonte, D., Schick, B., Addis, A., Mastroiacova, P., Mazzone, T., Matsui, D. and Koren, G. (1998). A prospective controlled multicentre study of clarithromycin in pregnancy. American Journal of Perinatology 15, 523-525
11. Ekland, E. H., Schneider, J. and Fidock, D. A. (2011). Identifying apicoplast-targeting antimalarials using highthroughput compatible approaches. The FASEB Journal 25, 3583-3593
12. Ho, P., Luo, X., Macauley, J. S., Grigor, M. R. and Wanwimolruk, S. (1998). In vitro hepatic metabolism of cyp3a-mediated drugs quinine and midazolam in the common brush-tailed possum (trichosurus vulpecula). Environmental Toxicology and Chemistry 17, 317-324
13. Johnson, J. D., Richard, A. D., Lucia, G., Miriam, L., Norma, E. R. and Norman, C.W. (2007). Assessment and continued validation of the malaria SYBR Green I-based fluorescence assay for use in malaria drug screening. Antimicrobial Agents and Chemotherapy 51, 1926-1933
14. Kalanon, M. and McFadden, G. I. (2010). Malaria, Plasmodium falciparum and its apicoplast. Biochemical Society Transactions 38, 775-782
15. Kazim, M., Puri, S. K. and Dutta, G. P. (1991). Comparative evaluation of blood schizontocidal activity of quinine and quinidine against drug resistant rodent malaria. Journal of Communicable Diseases 23, 254-256
16. King, S. M. (1995). Clarithromycin for children. Canadian Journal of Infectious Diseases 6, 69-70
17. Lell, B. and Kremsner, P. G. (2002). Clindamycin as an antimalarial drug: Review of clinical trials. Antimicrobial Agents and Chemotherapy 46, 2315-2320
18. Mathis, A., Wild, E. C., Boettger, E. C., Kapel, C. M. O. and Deplazes, C. P. (2005). The mitochondrial ribosome as target for macrolide antibiotic clarithromycin in the helminth Echinococcus multiocularis. Antimicrobial Agents and Chemotherapy 49, 3251-3255
19. Mathis, A., Wild, P., Deplazes, P. and Boettger, E. C. (2004). The mitochondrial ribosome of the protozoan Acanthamoeba castellanii is the target for macrolide antibiotics. Molecular and Biochemical and Parasitology 135, 225-229
20. Mirghani, R. A., Yasar, U., Zheng, T., Cook, J. M., Gustafsson, L. L., Tybring, G. and Ericsson, O. (2002). Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro: 3-hydroxylation by cyp3a4 is indeed the major metabolic pathway. Drug Metabolism and Disposition 30, 1368-1371
21. Na-Bangchang, K. and Karbwang, J. (2009). Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fundamental & Clinical Pharmacology 23, 387-409
22. Nand, N., Aggarwal, H., Sharma, M. and Singh, M. (2001). Systemic Manifestations of Malaria. Journal, Indian Academy of Clinical Medicine 2, 189-194
23. Newton, P., Keeratithakul, D., Teja-Isavadharm, P., Pukrittayakamee, S., Kyle, D. and White, N. (1999). Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. Transactions of Royal Society of Tropical Medicine & Hygiene 93, 69-72
24. Nielsen, T. L., Rasmussen, B. B., Flinois, J., Beaune, P. and Brosen, K. (1999). In vitro metabolism of quinidine: The (3 s)-3-hydroxylation of quinidine is a specific marker reaction for cytochromep-4503a4 activity in human liver microsomes. The Journal of Pharmacology and Experimental Therapeutics 289, 31-37
25. Pai, M. P., Graci, D. M. and Amesden, G.W. (2000). Macrolide-drug interaction: An update. Annals of Pharmacotherapy 34, 495-513
26. Pinto, A. G., Wanq, Y. H., Chalasani, N., Skaar, T., Kolwankar, D., Gorski, J. C., Lianqpunsaqul, S., Hamman, M. A., Arefayene, M. and Hall, S. D. (2005). Inhibition of human intestinal wall metabolism by macrolide antibiotics: Effect of clarithromycin on cytochrome P4503A4/5 activity and expression. Clinical Pharmacological Therapy 77, 178-188
27. Rodrigues, A. D., Roberts, E. M., Mulford, D. J., Yao, Y. and Ouellet, D. (1997). Oxidative metabolism of clarithromycin in the presence of human liver microsomes: Major role for the cytochrome p4503a (cyp3a) subfamily. Drug Metabolism and Disposition 25, 623-630
28. Sidhu, A. B. S., Valderramos, S. G. and David, A. (2005). Fidock PfMDR 1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Molecular Microbiology 57, 913-926
29. Singh, S., Srivastava, R. K., Srivastava, M., Puri, S. K. and Srivastava, K. (2011). In-vitro culture of Plasmodium falciparum: Utility of modified (RPNI) medium for drug-sensitivity studies using SYBR Green I assay. Experimental Parasitology 127, 318-321
30. Soyinka, J. O., Onyeji, C. O., Omoruyi, S. I., Owolabi, A. R., Sarma, P. V. and Cook, J. M. (2009). Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. British Journal of Clinical Pharmacology 69, 262-270
31. Sullivan, D. J., Jr., Gluzman, I., Russell, D. G. and Goldberg, D. E. (1996). On the molecular mechanism of chloroquine's antimalarial action. Proceedings of the National Academy of Sciences USA 93, 11865-11870
32. Suzuki, A., Iida, I., Hirota, M., Akimoto, M., Huguchi, S., Suwa, T., Tani, M., Ishizaki, T. and Chiba, K. (2003). CYP isoforms involved in the metabolism of clarithromycin in vitro: Comparison between the identification from the disappearance rate and that from formation rate of metabolites. Drug Metabolism and Pharmacokinetics 18, 104-113
33. Tripathi, R., Pandey, S. K. and Rizvi, A. (2011). Clarithromycin, a cytochrome P450 inhibitor, can reverse mefloquine resistance in Plasmodium yoelii nigeriensis infected Swiss mice. Parasitology 138, 1069-1076
34. Tripathi, R., Awasthi, A. and Dutta, G. P. (2005). Mefloquine resistance reversal action of ketoconazole-A cytochrome P450 inhibitor, against mefloquine resistant malaria. Parasitology 130, 475-479
35. Uzuegbu, U. E. and Emeka, C. B. (2011). Changes in Liver Function Biomarkers among Malaria Infected Patients in Ikeja Lagos State, Nigeria. Current Research Journal of Biological Sciences 3, 172-174
36. Ward, M. B., Sorich, M. J., Evans, A. M. and McKinnon, R. A. (2009). Cytochrome P450 Part 3: Impact of Drug-Drug Interactions. Journal of Pharmacy Practice and Research 39, 55-58
37. White, N. J., Looareesuwan, S., Warrell, D. A., Chongsuphajaisiddhi, T., Bunnag, D. and Harinasuta, T. (1981). Quinidine in falciparum malaria. Lancet 4, 1069-1071
38. Whitty, C. J. M., Chandler., Ansah, E., Leslie, T. and Staedke, S. G. (2008). Deployment of ACT antimalarials for treatment of malaria: Challenges and opportunities. Malaria Journal 7, (Suppl 1):S7
39. Wisedpanichkij, R., Chaijaroenkula, W., Sangsuwanb, P., Tantisawat, J., Boonpraserta, K. and Na-Bangchanga, K. (2009). In vitro antimalarial interactions between mefloquine and cytochrome P450 inhibitors. Acta Tropica 112, 12-15
40. Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H. and Meshnick, S. R. (2002). Epidemiology of drug-resistant malaria. Lancet Infectious Diseases 2, 209-218
41. World Health Organization. (2012). Update on Artemisinin Resistance -April. http://www.who.int/malaria/publications/atoz/arupdate042012. pdf
42. World Health Organization. (2006). Malaria Treatment Guidelines and Artemisinin Monotherapies. Geneva, Switzerland
43. World Malaria Report. (2011). http://www.who.int/malaria/world-malaria- report-2011/WMR2011-noprofiles-lowres.pdf
44. Zuckerman, J. M., Qamar, F. and Bono, B. R. (2009). Macrolides, ketolides, and glycylcyclines: Azithromycin, clarithromycin, telithromycin, tigecycline. Infectious Disease Clinics of North America 23, 997-1026